On November 11, 2025, PDS Biotechnology Corp entered into a securities purchase agreement to sell 5,741,000 shares of common stock at $0.91 each, along with warrants, expecting about $11.1 million in gross proceeds. The net proceeds will be utilized for research and development and general corporate purposes.